PRS54 - COST-EFFECTIVENESS ANALYSIS OF RESLIZUMAB FOR PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA INADEQUATELY CONTROLLED WITH HIGH-DOSE INHALED CORTICOSTEROIDS AND LONG-ACTING B2-AGONISTS IN SOUTH KOREA

Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.2448
https://www.valueinhealthjournal.com/article/S1098-3015(18)35750-4/fulltext
Title : PRS54 - COST-EFFECTIVENESS ANALYSIS OF RESLIZUMAB FOR PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA INADEQUATELY CONTROLLED WITH HIGH-DOSE INHALED CORTICOSTEROIDS AND LONG-ACTING B2-AGONISTS IN SOUTH KOREA
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35750-4&doi=10.1016/j.jval.2018.09.2448
First page :
Section Title :
Open access? : No
Section Order : 1803
Categories :
Tags :
Regions :
ViH Article Tags :